Research and Development Agreements - Schedule of Research and Development Revenue from Related Party Relates to Revenue from Research and Development Agreements (Detail) - USD ($) $ in Thousands |
3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2022 |
Sep. 30, 2021 |
Sep. 30, 2022 |
Sep. 30, 2021 |
|
Revenue Recognition [Line Items] | ||||
Total research and development revenue | $ 4,240 | $ 2,379 | $ 17,143 | $ 20,733 |
Millennium Pharmaceuticals, Inc. | ||||
Revenue Recognition [Line Items] | ||||
Total research and development revenue | 0 | 0 | 2,586 | 13,136 |
Millennium Pharmaceuticals, Inc. | Takeda Development Agreement | ||||
Revenue Recognition [Line Items] | ||||
Total research and development revenue | 0 | 0 | 0 | 13,114 |
Millennium Pharmaceuticals, Inc. | Takeda Multi Target Agreement | ||||
Revenue Recognition [Line Items] | ||||
Total research and development revenue | $ 0 | $ 0 | $ 2,586 | $ 22 |
X | ||||||||||
- Definition Research and development revenues from collaboration agreements. No definition available.
|
X | ||||||||||
- Definition Revenue recognition. No definition available.
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|